These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12955684)

  • 1. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
    Richardson D; Lindley EJ; Bartlett C; Will EJ
    Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the iron metabolism and effectiveness of anemia treatment in patients on maintenance hemodialysis performed based on polysulfone and helixone dialyzers].
    Sobaszek-Pitas M; Krzanowska K; Sułowicz W
    Przegl Lek; 2014; 71(8):418-22. PubMed ID: 25546912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
    Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
    Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
    McCarthy JT; Jenson BM; Squillace DP; Williams AW
    Am J Kidney Dis; 1997 Apr; 29(4):576-83. PubMed ID: 9100048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin.
    Debska-Slizień A; Owczarzak A; Kunicka D; Lysiak-Szydłowska W; Rutkowski B
    Int J Artif Organs; 2003 Jan; 26(1):33-8. PubMed ID: 12602467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
    J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.